The company develops senolytic compounds that selectively eliminate senescent cells, which are implicated in various age-related diseases. Their research focuses on identifying and advancing these compounds to improve cellular resilience and slow tissue degeneration, supporting healthier aging.
Funding
Funding not disclosed
Founders
Product
Problem
As organisms age, cells can enter a state of senescence, accumulating in tissues and releasing harmful signals that disrupt normal function. In the brain, these senescent cells contribute to inflammation, impair mood and memory, and are implicated in various neurological and psychiatric diseases. Current treatments do not specifically target these dysfunctional cells.
Solution
Bough Biosciences is developing senolytic therapies designed to selectively eliminate senescent cells in the brain, addressing the root cause of age-related cognitive decline and neurological disorders. By studying the molecular fingerprints of senescent cells, they computationally model disease-specific cellular senescence to identify compounds that can alleviate the burden of these cells. Their approach aims to restore healthy brain function by clearing the "clutter" caused by senescent cells, offering a novel therapeutic strategy for neurological and neuropsychiatric diseases.
Target Audience
The primary target audience includes researchers and clinicians focused on developing treatments for neurological and neuropsychiatric diseases associated with aging and cellular senescence.
Features
- Identification of unique molecular fingerprints of senescent cells.
- Computational modeling of disease-specific cellular senescence.
- Discovery of potent senolytic compounds targeting senescent cells in the brain.
- Development of therapies to restore healthy brain function.